SCHEMBL740311

SCHEMBL740311

COC(=O)c1cncc(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 1.00
HCAR2 Q8TDS4 1/20 0.62
CYP2A6 P11509 1/20 0.54
ALDH1A1 P00352 2/20 0.52
TDP1 Q9NUW8 2/20 0.50
CYP11B1 P15538 2/20 0.49
CYP11B2 P19099 2/20 0.49
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMYD3 Q9H7B4 2/20 0.46
KDM4E B2RXH2 2/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL28626735 0.98 ATM (0.96) ATMHCAR2CYP2A6ALDH1A1TDP1
SCHEMBL56951 0.87 ATM (0.77) ATMCYP2A6ALDH1A1TDP1CYP11B1
Hydrochloric Acid SCHEMBL2298745 0.85 ATM (0.74) ATMCYP2A6ALDH1A1TDP1CYP11B1
SCHEMBL28025756 0.82 ATM (0.70) ATMHCAR2CYP2A6ALDH1A1CYP11B1
SCHEMBL27994556 0.82 ATM (0.70) ATMHCAR2CYP2A6ALDH1A1CYP11B1
SCHEMBL3715051 0.82 ATM (0.69) ATMCYP2A6ALDH1A1TDP1CYP11B1
SCHEMBL6979199 0.81 CYP2C19 (0.72) ATMHCAR2ALDH1A1CYP2C9CYP2C19
SCHEMBL431955 0.80 ATM (0.67) ATMCYP2A6ALDH1A1TDP1CYP11B1
SCHEMBL56952 0.80 ATM (0.67) ATMHCAR2CYP2A6ALDH1A1TDP1
SCHEMBL30067639 0.80 ATM (0.67) ATMHCAR2CYP2A6ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117720458-A Preparation method of rupatadine intermediate 5-methyl-3-pyridine methanol 北京嘉林药业股份有限公司 2024-03-19 CN claimed
CN-117417291-A Preparation method of rupatadine fumarate intermediate 5-methyl-3-hydroxymethylpyridine 北京嘉林药业股份有限公司 2024-01-19 CN claimed
CN-113264872-B Preparation method of rupatadine fumarate intermediate 5-methyl-3-hydroxymethylpyridine 北京嘉林药业股份有限公司 2023-09-08 CN claimed
CN-104163786-A Method for preparing 5-methyl-3-bromomethylpyridine hydrobromide SHANGHAI INST TECHNOLOGY 2014-11-26 CN claimed
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 US disclosed
US-12378200-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2025-08-05 US disclosed
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ORSOBIO INC (US) 2025-05-08 US disclosed
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD VIB VZW (BE) 2025-04-10 US disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-03-06 US disclosed
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP disclosed
EP-0985671-A1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-03-15 EP disclosed
CN-1244130-A Hapten-carrier conjugates for drug abuse therapy and methods of making the same IMMULOGIC PHARMA CORP (US) 2000-02-09 CN disclosed
US-6018046-A SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-01-25 US disclosed
US-5741802-A FOR TREATMENT OF MEMORY LOSS UNIVERSITY OF FLORIDA (US) 1998-04-21 US disclosed
EP-0659078-A4 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. UNIV FLORIDA (US) 1996-04-24 EP disclosed
EP-0659078-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 1995-06-28 EP disclosed
WO-1994005288-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM UNIVERSITY OF FLORIDA (US) 1994-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378200-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ALDH7A1, ACMSD, AMD1 ATM 2021/4885HCAR2 910/4885CYP2A6 1270/4885
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ACMSD, ALDH7A1, ALAD ATM 1567/4885HCAR2 839/4885CYP2A6 797/4885
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ATM 316/4885HCAR2 3980/4885CYP2A6 3991/4885
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS BCL6, BCL6B, BCOR ATM 3247/4885HCAR2 2829/4885CYP2A6 1004/4885
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ATM 400/4885HCAR2 2737/4885CYP2A6 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.